Skip to content
10-Q

Quarterly Report

Aspire Biopharma Holdings, Inc. ASBP ASBPW

0001493152-26-023802

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 13, 2026 1.3M sh
Shares Diluted Q1 2026 · Mar 31, 2026 156.69K sh
Shares Diluted Q1 2026 · Mar 31, 2025 31.58K sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$3.04M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $5.86M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $1M
Stockholders Equity Q1 2026 · Mar 31, 2026 $3.87M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$6.38M
Current Liabilities Q1 2026 · Mar 31, 2026 $3.15M
Current Liabilities Q1 2026 · Dec 31, 2025 $7.59M
Total Liabilities Q1 2026 · Mar 31, 2026 $3.25M
Total Liabilities Q1 2026 · Dec 31, 2025 $7.69M
Current Assets Q1 2026 · Mar 31, 2026 $7.12M
Current Assets Q1 2026 · Dec 31, 2025 $1.31M
Total Assets Q1 2026 · Mar 31, 2026 $7.12M
Total Assets Q1 2026 · Dec 31, 2025 $1.31M
Eps Diluted Q1 2026 · Mar 31, 2026 −$20.57
Eps Diluted Q1 2026 · Mar 31, 2025 −$504.88
Eps Basic Q1 2026 · Mar 31, 2026 −$20.57
Eps Basic Q1 2026 · Mar 31, 2025 −$504.88
Sga Expense Q1 2026 · Mar 31, 2026 $1.02M
Rd Expense Q1 2026 · Mar 31, 2026 $296.72K
Net Income Q1 2026 · Mar 31, 2026 −$3.22M
Operating Income Q1 2026 · Mar 31, 2026 −$1.65M
Operating Income Q1 2026 · Mar 31, 2025 −$15.56M
Gross Profit Q1 2026 · Mar 31, 2026 $5.75K
Cost Of Revenue Q1 2026 · Mar 31, 2026 $22.6K
Revenue Q1 2026 · Mar 31, 2026 $28.35K